Topspin Partners

Total investments

52

Average round size

24M

Portfolio companies

30

Rounds per year

2.26

Lead investments

11

Follow on index

0.42

Exits

15

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyAnalyticsHealth CareGeneticsManufacturingMedical DeviceMedicalPharmaceuticalTherapeuticsBiopharma

Summary

The leading representative office of defined VC is situated in the Roslyn Heights. The company was established in North America in United States.

Among the most popular portfolio startups of the fund, we may highlight Alector, NGM Biopharmaceuticals, Celmatix. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, Genetics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

Considering the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2015. The common things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2019. This Topspin Partners works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Topspin Partners, startups are often financed by OrbiMed, OUP (Osage University Partners), Versant Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Venrock, Third Rock Ventures. In the next rounds fund is usually obtained by The Column Group, OrbiMed, GV.

The fund was created by Leigh J. Randall, Leo Guthart, Stephen M. Lebowitz. Besides them, we counted 5 critical employees of this fund in our database.

Show more

Investments analytics

Analytics

Total investments
52
Lead investments
11
Exits
15
Rounds per year
2.26
Follow on index
0.42
Investments by industry
  • Biotechnology (34)
  • Health Care (21)
  • Pharmaceutical (15)
  • Genetics (12)
  • Therapeutics (10)
  • Show 49 more
Investments by region
  • United States (50)
Peak activity year
2015
Number of Unicorns
2
Number of Decacorns
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
14
Avg. valuation at time of investment
122M
Group Appearance index
0.83
Avg. company exit year
9
Avg. multiplicator
2.14
Strategy success index
0.70

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Crisp 11 Oct 2022 E-Commerce, Marketplace, Grocery Late Stage Venture 88M North Holland, Amsterdam, Netherlands
Immune Design 30 Oct 2013 Biotechnology, Health Care, Therapeutics Late Stage Venture 49M United States, Washington, Seattle
Pionetics 23 May 2003 Biotechnology, Food and Beverage, Health Care, Robotics, Manufacturing, Electronics, Water, Water Purification Early Stage Venture 3M United States, California
XAPP AI 09 Jul 2021 Software, Artificial Intelligence, Machine Learning, Computer Seed 3M United States, Virginia, Arlington

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.